Novartis in Switzerland

Home , Canton of Geneva, Fribourg, Northwestern Switzerland, Novartis

Novartis in Switzerland Novartis in der Schweiz Novartis en Suisse Dear reader, At Novartis, exploring new paths and improving and extending people’s lives is what we strive toward every single day. Switzerland has always served as a key location for driving innovation at our company. It is home to our global headquarters, as well as central branches for the research, development and production of innovative drugs and therapies. By way of example, we invested approximately CHF 3.4 billion into research and development alone at our Swiss sites last year. To ensure the success of Novartis over the long term, we are evolving into a focused medicines company. Per- sonalized therapies, new digital technologies and strong partnerships with research institutions will be at the core of our business. This evolution is leading to changes in production: traditional production methods are becoming less relevant, while new platforms are increasing in importance. Over the next few years, for example, we are planning to invest up to CHF 90 million into a new platform for the production of cell and gene therapies in Stein, Switzerland. This pocket-size brochure has been designed to provide you with current information about these key activities and other developments at our company in Switzerland and around the world. We hope you enjoy the read. Matthias Leuenberger Country President Novartis Switzerland Our strategic priorities Content

Novartis at a glance Novartis a glance at What drives us 4 Unleash the power Deliver transformative At work worldwide, at home in Switzerland 6 of our people innovation One of the world’s largest pharmaceutical companies 11 Procurement of goods and services 12 Facts and ﬁgures 2018 13 Our sites Our sites Sites in Switzerland 14 Location profles 16 Embrace operational Go big on data excellence and digital Employer

Working at Novartis 21 Employer Novartis employees in Switzerland 22 Starting a career 23 Our medicine The path to a new medicine 25 Build trust with society Reimagining medicine 28

Therapeutic areas 30 medicine Our Research and development 32 Excellence in manufacturing 36 Our responsibility Supporting science 37 Our contribution to the environment and society 39

Sponsoring and donations 47 responsibility Our 6

and ideas in our company. time money, their invest who to those reward aim We also possible. as people many to as them ways to deliver new ﬁnd and treatments breakthrough develop and discover We issues. healthcare challenging most of society’s some to address technology and science innovative We use lives. people’s extend and to improve medicine We reimagine What drives us world, and is based on four pillars: four on based is and world, the around patients million 200 approximately representing organizations patient 40 than more with of adialog outcome the is It awhole. as company the for principle guiding the now is and 2015, from statement patient of our evolution the represents promise This work. day-to-day our into providers care and of patients requirements the integrate better to order in principles Group-wide weadopted 2018, In to Patients Caregivers and Commitment Our understanding the patient patient the understanding Conducting responsible community perspective Respecting and clinical trials

importance of transparency Expanding access Expanding to our medicines Recognizing the and reporting

Novartis at a glance 8

worldwide, but also in Switzerland. in also but worldwide, only not presence our increasing weare (AAA), Applications the radiopharmaceutical company Advanced Accelerator and AveXis company therapy gene of the acquisition the With cines and therapies. medi innovative on here research in engaged are world the over all from Scientists sites: research important most of our one is campus The division. Medicines Innovative global the of office head the and headquarters company our including Basel, in based are units international Many Switzerland. in generated are sales total pany’s com of the 2% Around 1996. in established was Novartis become a stable driver of the economy in Switzerland since has which industry, pharmaceutical of the success to the employees who work here make an important contribution so or 13,000 The of Novartis. hubs distribution and duction pro research, important most of the one is Switzerland Importance of Switzerland around 130,000 research and development of new medicines. Worldwide, the in lie skills core Our world. the around societies and of patients needs changing the to address solutions medical We offer years. 150 over back stretch These roots. Swiss its to commitment astrong with company aglobal is Novartis at Switzerland in home At work worldwide, people of 147 nationalities work at Novartis. work of 147 nationalities people

- -

excellence. operational promote and to efficiency to increase help organizations functional our level, strategy. global At the of our part acrucial is and business of our core the forms customer relations. Research and development (R&D) strong and reach aglobal with –segments generics and Novartis focuses on innovative patent-protected medicines model business Our

o Ph z Corpo a rate rm f a un c c e ti u o t

n ic

M s a a ls

R n

c o

t u

g D

(

T B

O u

) i

( ) N S B

O nc ology 9

Novartis at a glance 10

pending approval from shareholders and regulators. Alcon, off to spin intention the announced Novartis 2018, In devices. care of eye selections widest world’s the of one offers Alcon affordable generics and biosimilars. quality, high professionals healthcare and patients offers Sandoz cardio-metabolic. tology and dermatology, neuroscience, respiratory and ments in the areas of ophthalmology, immunology, hepa Novartis Pharmaceuticals diseases. rare and of cancers variety Novartis Oncology units: business two comprises division The Innovative Medicines Our divisions p. 10 p. focuses on patented treatments for a for treatments patented on focuses focuses on patented treat

- - Novartis Business Services (NBS) sites. production our across planning capacity and allocation resource optimize us NTO helps products. handles manufacturing of innovative medicines and Sandoz Novartis Technical Operations (NTO) ing finance, human resources, legal and communications. includ of expertise, areas specific in enterprise the support Corporate functions ing drive efficiency, simplification, standardizationand quality. consolidates across support services our organization, help and partners. researchers by our discovered medicines of new opment Global Drug Development of medicine. practice the change can that drugs new discovering on focuses NIBR of Novartis. engine innovation Novartis Institutes for BioMedical Research (NIBR) is divided into two organizations: Research and development (R&D) reach aglobal with Functional organizations p. 33 p.

p. 35 p. organization oversees the devel p. 36 p. is the the is - - - 11

Novartis at a glance 12

The planned spinoff would enableNovartis and Alcon The future of Alcon York Stock Exchange (NYSE). Alcon listed on the SIX Swiss Exchange (SIX) and the New New the and (SIX) Exchange Swiss SIX the on listed Alcon medi focused aleading, to build strategy of our part As of Fribourg, with other important sites in Rotkreuz and and Rotkreuz in sites important other with of Fribourg, canton the in incorporated be will it and of Geneva canton completion of the planned spinoff, Alcon will remain com care division into a standalone company with shares in in shares with company astandalone into division care eye Alcon the off to spin planning weare company, cines Completion of the planned transaction is subject to general market conditions, regulatory approvals, f to focus fully on their respective growth strategies. On On strategies. growth respective their on fully to focus mitted to Switzerland. Its global headquarters will be in the the in be will headquarters global Its to Switzerland. mitted Schaffhausen. by the Board of Directors and shareholder approval. nal endorsement - - 4 7 (by sales of pharmaceutical products) pharmaceutical of sales (by world the in companies pharmaceutical largest 10 The second largest pharmaceutical company in the world. the is Novartis sales, pharmaceutical of global terms In companies pharmaceutical ofOne world’s the largest 1 10 2 6 3 9 8 5 Source: IMS PADDS Monthly, January 2019 (data from January – November 2018) –November January from (data 2019 January Monthly, PADDS IMS Source: Johnson & Johnson AbbVie GlaxoSmithKline Gilead Sciences Sano Novartis Merck &Co Merck Roche P Lilly f zer f GB Switzerland Switzerland France USA USA USA USA USA USA USD billion USD 35.8 26.3 34.4 35.4 26.0 46.5 41.6 4.1 4 5.1 3 39.7 13

Novartis at a glance 14

Top 1 Top Zug (ZG) Zug (ZH) Zurich Aargau (AG) orders worth around CHF 2.4 billion in the 26 cantons of cantons 26 the in billion 2.4 CHF around worth orders of goods and services from suppliers, including many many including suppliers, from services and of goods Vaud (VD) Vaud than four further indirect jobs. In 2018, the company placed Geneva (GE) Geneva goods and services and goods vices, Novartis indirectly secures more than 58,000 jobs jobs 58,000 than more secures indirectly Novartis vices, Procurement of Switzerland. SMEs. Through the procurement of products and ser and of products procurement the Through SMEs. Novartis offers jobs not only directly, but also as a buyer buyer as a also but directly, only not jobs offers Novartis Nidwalden (NW) (BE) Berne (BL) Basel-Land Neuchâtel (NE) (BS) Basel-Stadt in Switzerland; behind each job at Novartis, there are more more are there at Novartis, job each behind Switzerland; in Purchases by canton  CHF million CHF 486 223 142 743 271 211 40 84 29 55 - 38 Employees development and Research Facts figures and 2018 Sales 10 2 % 2 % % % worldwide 130,000 in Switzerland 13,000 worldwide bn 8.9 CHF in Switzerland bn 3.4 CHF worldwide 50.7 bn CHF in Switzerland bn 0.8 CHF 3 plant, and equipment Investment in property, Current income taxes 12 9 % % worldwide 1.7 bn CHF in Switzerland bn 0.2 CHF worldwide bn 1.8 CHF in Switzerland 0.7CHF bn 15

Novartis at a glance 16

9 8 7 6 5 4 3 2 1 Sites Switzerland in

* Novartis Pharmanalytica (TI) Locarno Alcon Management * Advanced Accelerator Applications (AAA) (GE) Geneva Alcon Pharmaceuticals * (FR) Fribourg • • • units business Swiss of office Head (ZG) Rotkreuz AveXis (ZH) Zurich Alcon Grieshaber * Schaffhausen (SH) Production (AG) Stein Production Schweizerhalle (BL) Production Research and development Division Medicines Innovative of office Head Company headquarters (BS) Basel pending approval from shareholders and regulators. Alcon, off spin to intention the announced Novartis 2018, In Alcon * Sandoz Innovative Medicines 8 7 1 2 3 6 5 4 9 17

Our sites 18 shape the character of this former industrial complex. now zones encounter and work diverse with landscapes laboratory models and office and teams. Forward-looking takes place across divisions work where management, and for research, development center ultramodern an is pus Cam Novartis The Novartis. of headquarters global the to home is site Basel The Novartis Campus Basel St. Johann (BS) Location profiles - laboratory technologies and released for further processing. state-of-the-art using systems in technically complex special medicines. These are produced 25 around for here products ingre produces active pharmaceutical Novartis 1930s. of the end the since at Schweizerhalle produced been have Products Production Schweizerhalle (BL) dients and intermediate 19

Our sites 20

billion tablets, capsules, ampoules, pre 2 year, than more Each here. dosage forms are located sterile and solid for facilities pharmaceutical manufacturing Two medicines. of innovative launch and manufacturing the for site important strategically a is Basel, from Rhine the up kilometers 30 about Stein, Production (AG) Stein gene therapies from 2020. from therapies gene and cell personalized with Europe in patients supply will A biotechnology center is also under construction, which countries. different 150 than to site more Stein the from shipped and and autoinjectors are manufactured, inspected, packaged

f lled syringes, vials lenses and contact lens care products. care lens contact and lenses implants, surgical equipment and instruments, and contact markets pharmaceuticals, medical products, such as lens f the in leader market aglobal is Alcon pioneer in biosimilars. a also is Sandoz areas. indication major the all covers and sizes pack and strengths dosage different 1,000 around in products 200 than more includes portfolio product The Switzerland. in producers generics leading of the one is Sandoz Pharmaceuticals diseases. rare and tology hema of oncology, ﬁelds the in Switzerland in medicines Novartis Oncology disorders. dermatology, ophthamology, cardiology and respiratory important therapeutic areas include neurology, immunology, most The Switzerland. in icines of around 80 prescription med marketing the for responsible Novartis Pharmaceuticals Novartis Pharma Schweiz Rotkreuz. in building office business units share a modern Swiss of the Employees business units Swiss of office Head (ZG) Rotkreuz

markets more than 20 prescription is is - eld of eye care and and of eye care eld - 21

Our sites 22

ysis of potential duplicate or counterfeit products. counterfeit or duplicate of potential ysis anal and inspection the as well as at Novartis technologies Locarno handles the implementation of new analytical bers and developing new analytical methods. ity samples in climate cham stabil storing reports, stability writing products, Novartis for tests release speciﬁc and tests stability performing include ties Pharmanalytica’s responsibili site. Locarno at the products Novartis 110 than more on Analytical tests are performed Pharmanalytica (TI) Locarno - - - - • • • • • • ment programs, and individual performance appraisals. guide us in our recruitment processes, employee develop help They culture. company our underpin values six Our values Our unbossed. cultivate a company culture that is inspired, curious and we and people of our power the toWe unleash strive culture Our diversity, energy and creativity are crucial to our success. whose people, our is of Novartis strength greatest The Working at Novartis Integrity Courage Performance Collaboration Quality Innovation - 23

Employer 24

15 GERMANY 17 FRANCE in Switzerland in Novartis employees 68 Employees’ place of residence SWITZERLAND site in Stein. in site company’s the at therapies gene and cell for center European new the for quali highly 450 to up create to aiming is it time, same the At 2022. by Switzerland in services internal and production in jobs 2,150 estimated an cut to plans Novartis efforts, restructuring its of part As % % % 13,000 74% of them are Swiss. are 74% them of employees deal with employees work the Swiss market. market. Swiss the in Switzerland. 460

are Swiss nationals. Swiss are functions are held of management work part time. part work of employees by women. by 37 29 12 % % f % ed positions positions ed

• • • • • • to: offered are and ing train of academic stage at every available are Internships Novartis. at career their starting in interested are who sciences social and law, psychology of economics, ﬁelds the in specialists require However, wealso engineering. and medicine science, of natural ﬁelds the in graduates university and students for particular in we look business, core our For Students and university graduates www.novartis.com/career vacancies are regularly advertised on our careers portal: career diverse opportunities for development. Current their on out starting people offer We therefore future. Talented, engaged and responsible young people are our Starting acareer Postdocs students MBA Graduates students degree Master’s Bachelor’s degree students Prospective students - 25

Employer 26

• • • • • • • • • • occupations: following the in skills and knowledge with trainees We provide production. and development and research in lies training of this focus main The time. given any at apprentices 280 around trains year. Novartis Altogether, each at Novartis apprenticeship an start trainees 90 Around Vocational training Polymechanic Logistician Commercial assistant Computer scientist Electronics engineer assistant Office Automation engineer Chemical and pharmaceutical technician Laboratory technician in chemistry Laboratory technician in biology improve or extend lives. lives. extend or improve to significantly potential the with projects on focusing sources, external and of internal a variety from ideas ising prom advance researchers Our years. many –over clinic the in later and laboratory the in –first tested and refined incubated, is which idea, an as begins treatment Each The path to anew medicine - 27

Our medicine 28

research Preclinical and design research Drug Target selection Discovery Compounds > 10,000 Compounds < 250 Application submitted (IND) Drug New Investigational Compounds < 5 (Proof ofConcept) (Proof PoC Iand Phase and/or patients volunteers healthy 20 – 100 Clinical trials Phase II patients 100 – 500 Phase III patients 1,000 – 5,000 Application submitted Biologics License Application / Drug New authority regulatory by Review Submission Evaluation 1 – 15 years 1 – 15 medicine a new of Approval Manufacturing research surveillance and Post-marketing Phase IV Post-approval 29

Our medicine 30

to develop breakthrough therapies. ability our to set Together, increase are steps space. these healthcare digital and data the into push our accelerated our operations, expanded our therapeutic platforms and we strengthened 2018, In company. medicines a leading to remain portfolio our to focus steps important taking are whywe is That efficiency. more with –and society and patients for outcomes health better produces that vation inno true of delivering importance the heighten trends These diseases. chronic in arise fueling longer, living are people and to grow continues population world’s the time, same At the healthcare. in advances exciting driving Surging innovation in medical science and technology is Focusing our company Reimagining medicine - support of our global teams. teams. global of our support in actions to direct trials ongoing all on updates real-time a control room located on Basel Campus that receives to more effectively plan and run clinical trials. It includes ations, including clinical trials of experimental the radiopharmaceutical company Advanced Accelerator and AveXis company therapy gene of the acquisition the With therapies. gene and cell new technology platforms and advanced our portfolio of signi year, wemade Last tions. now take different forms from conventional pills and injec medicines that illustrates therapeutics of digital rise The New technology platforms development our run and way weplan the improve to intelligence artificial using we are instance, For quickly. analytics data and technologies digital using weare R&D, In Data digital science and technologies A new system called Nerve Live uses predictive predictive uses Live Nerve called system A new to help find new drugs and bring them to patients more more to patients them bring and drugs new find to help only worldwide, but also in Switzerland. in also but worldwide, only not presence our increasing weare (AAA), Applications f cant investments in several several in investments cant treatments. treatments. analytics oper

- -

Our medicine 32

Therapeutic areas major submissions, we made signiﬁcant progress in 2018. in progress signiﬁcant we made submissions, major 20 key and in markets approvals major 20 With treatments. transformative to produce potential the has knowledge and experience our where areas disease in needs patient to address medicines innovative produce and We develop arthritis, spondylitis). ankylosing and chronic rheumatic diseases (psoriatic of psoriasis treatment the on is focus main In recognize cancer cells and destroy them. patient are selectively reprogrammed to of the T-cells the which in therapy, T-cells) CAR-T (chimeric antigen receptor-modi A particularly innovative development is marrow. bone and blood of the parts or kidney, lung, skin, breast, the example, options for various cancers affecting, for treatment on research in engaged are and oncologyIn and hematology, immunology and dermatology, we offer weoffer our f ed vative therapies to combat malaria. infectiousIn diseases, other things. increased intraocular pressure, amongst and diseases retinal with patients for options eye-care the In In migraine. and sclerosis of multiple treatment the with neurology,In we are occupied above all attack. aheart had have or failure heart from suffer who patients on cardiovascular diseases, In asthma. allergic and (COPD) disease pulmonary obstructive of chronic treatment the for portfolio lished respiratory diseases, division, we offer treatment treatment weoffer division, we focus on inno on wefocus we have an estab an wehave our focus is is focus our - - 33

Our medicine 34

ophthalmology. f the in research clinical and research basic both of advancing aim the with (IOB) Basel Ophthalmology Clinical and of Molecular Institute the founded Novartis Basel, Hospital University and of Basel University the with partnerships with companies and universities. Together by store great sets Novartis innovation, for capacity and expertise To scientiﬁc our country. this expand in billion 3.4 of CHF atotal weinvested 2018, In development. and research Novartis for akey is location Switzerland worldwide. products of new number asubstantial launch to weplan few years, next the In products. established for formulations new or indications additional and products new potential including development, of clinical phases different in projects 200 than more contains pipeline Our Research development and

eld of eld • • • • • • • • • • In Switzerland our key partners are: world. the throughout institutions research private maintains more than 300 partnerships with universities and NIBR organization, global its With system. immune and skin of musculoskeletal disorders, cancer, and diseases of the treatment the as such areas in breakthroughs to achieve uses pioneering methods and cutting-edge technology Basel in Research professionals. business and physicians scientists, of NIBR’s third, one or 2,200, than to more home is and globally locations key research of NIBR’s one is site Basel The patients. for breakthroughs therapeutic produce to help potential the have that technologies new scienti across collaborating of Novartis, engine innovation the is (NIBR) Research BioMedical for Institutes Novartis The Novartis Institutes for BioMedical Research Research in Switzerland Northwestern Switzerland (FHNW) (FHNW) Switzerland Northwestern University of Applied Sciences, Swiss Federal Institute of Technology Lausanne Swiss Federal Institute of Technology Zurich University Hospital Zurich University of Zurich University of Berne University Hospital Basel University of Basel Institute Scherer Paul Friedrich Miescher Institute for Biomedical Research (FMI) f c and organizational boundaries, and use powerful powerful use and boundaries, organizational c and

Our medicine 36

research and biomedical practice. academic between interface at the is foundation the Basel, of University the and Research BioMedical for Institutes Novartis the with association its Through neurobiology. and epigenetics biology, quantitative on focuses institute The disease. and health in lying molecular mechanisms of cells and organisms involved under the into to look technology latest the uses institute and employs around people. 330 The world-renowned 1970, conducts basic research in the ﬁeld of biomedicine in afoundation as Basel in established was which (FMI), The Friedrich Miescher Institute for Biomedical Research Friedrich Miescher Institute for Research Biomedical - the aim of greater efficiency and effectiveness. and efficiency of greater aim the with technologies, new and practices best procedures, and projects. It also drives the adoption of common standards development promising most to the resources allocate we ensures and pipeline our in products new potential evaluates regularly GDD partners. and researchers our by discovered medicines of new development the sees over organization (GDD) Development Drug Global The Development of breakthrough medicines in Switzerland in 2018. in Switzerland in conducted by Novartis patients890 were involving around TRIALS 69

- 37

Our medicine 38

start of 2020. start at the Switzerland and Europe in to patients available to be f The therapies. gene and cell innovative for there facility production asophisticated ing establish we are and site, akey to be launch continue will Stein in site Our location. one in production pharmaceutical f Our continuous manufacturing technique in Basel is the tions to reimagine manufacturing. solu innovative and new for look We continuously industry. the in manufacturer leading the to be is aspiration Our year. every countries to 150 units 70 billion around supply we In total, efficiently. and safely time, every time, on delivered are they ensure and products, cost-effective quality, high we manufacture sites, 60 of over network aglobal With performance. and growth business driving in role acritical (NTO) plays Operations Technical Novartis Excellence manufacturing in rst in the industry to integrate all steps of chemical and and of chemical steps all to integrate industry the in rst rst of these are scheduled scheduled are of these rst - - what it is like to think and work in ascienti in work and to like think is it what into insights gripping with them year, each providing pupils tional establishment has welcomed around 4,000 school educa the founding, its Since Switzerland. in kind of its ity f the was Lab School Novartis the 1993, in Opened an industrial research environment. in medicine and biology to chemistry, relating experiments to perform laboratory of the advantage take can countries neighboring and Switzerland over all from classes School Basel. in site Novartis of the heart at the located furnishings modern with laboratory open an is Lab School Novartis The Novartis School Lab Supporting science f c setting. rst facil rst - - 39

Our responsibility 40

land’s attractiveness as a research location. to encourage unconventional thought and boost Switzer aiming is Novartis program, this sector. Through sciences life Swiss the in unique way is this in research Supporting funding schemes. problems and solutions within the con scienti their to explore achance given rarely are who Switzerland in researchers for designed is It proposals. project unorthodox to support program FreeNovation the up set has Foundation Research Novartis the why is This programs. funding research today’s in actions and thoughts unconventional for room little is there this, Despite rein. free creativity their to give able are who of people spirit pioneering to the due but targets, strict by setting not occur key breakthroughs many of science, world the In FreeNovation f nes of conventional f c - approaches to strengthen healthcare systems. healthcare to strengthen approaches based on society’s healthcare needs, and supporting access models, refocusing research and development and pricing innovative adopting include strategies These globally. medicines new our deliver and develop weresearch, how into strategies access integrate to systematically Principles Access Novartis the to establish decided we therefore late 2017, In impact. to maximize necessary is approach systematic more and however,We abolder that realize, programs reached 24 million patients globally. models for more than two decades. In 2018, our access access innovative pioneering been wehave and healthcare, to to access commitment along-standing has Novartis Expanding access to healthcare to healthcare worldwide and to do business responsibly. access is to expand effort of this Akey part challenges. care health greatest world’s of the some to tackle seeks Novartis environment society and contributionOur to the - 41

Our responsibility 42

than 3 million monthly treatments in f in treatments monthly 3million than more delivered wehave program, of the start the Since prevention and diagnostic capability. to improve ground the on partners with works Access Novartis products, affordable to providing addition In month. per treatment 1per USD for sector public the in providers healthcare other and NGOs governments, to products of 15 aportfolio weprovide 2015, in launched program Access Novartis of our part as challenge, this with countries die of noncommunicable diseases. To help cope Every year more than 30 million people in developing Novartis Access ve countries. patients with this program. this with patients million 20 than more year, we reached Last of malaria. health camps pro without malaria with –to patients treatments pediatric lion mil 370 –including treatments million 900 nearly provide to organizations various with cooperated we have 2001, played a pioneering role in helping ﬁght malaria. Since has Initiative Malaria Novartis the years, 20 last the Over Novartis Malaria Initiative sessions. More than 700,000 people attended speci education health through Vietnam and Kenya India, in developing countries. In 2018, we reached 7.8 million people promoting health education and access to medical care in of goal the ourselves set we have program, this With Novartis Healthy Family f t, thereby helping to substantially reduce the burden burden the reduce to substantially helping thereby t, . f c - 43

Our responsibility 44

improve access to healthcare in low-income communities. and systems healthcare to strengthen Institute, Health Public Tropical and Swiss the and of Basel University the including partners, global with works Foundation Novartis The Novartis Foundation improve early diagnosis. early improve to interventions and tools new researching for action 200,000 newly diagnosed cases – through coordinating annual the –and transmission to interrupt wework Leprosy, Zero for Partnership Global of the member afounding as Now, by Novartis. donated therapy, multidrug free with worldwide patients million 16 reaching leprosy, eliminate to years 30 for worked have Foundation the and Novartis Leprosy by 2019. coverage nationwide to ensure this to expand is aim The country. the around centers seven has currently program telemedicine the of Healthy, Ministry Ghana by the Established to 71%. 36% from rose monitored was tension hyper whose participants of those number the months, 12 for program the in part took who patients Among services: of community value the demonstrate study ComHIP the of results latest The salon. at ahair or shops in urements patient’s surroundings, e.g. taking blood pressure meas to the localized approaches service novel and tools digital using diseases to non-infectious treat strategies innovative (ComHIP) and our telemedicine program in Ghana employ Our Hypertension Community-based Improvement Project Hypertension and urban health -

- which was valued at USD 115 million for 2017. for million 115 at USD valued was which chain, supply and operations of our impacts waste and water carbon, by the measured as impact, environmental negative our to minimize steps taking weare time, same At the million. 522 at USD valued –was safety occupational Our social impact – including employee development and 2017. in economy Swiss to the billion 22.7 USD contributed activities our valuation, impact FES to the According Report. Society in Novartis 2018 the in found be can odology meth evolving of the explanation Afull True approach. Value a on builds partners, external with co-developed was which valuation, impact Our terms. monetary in to society costs and beyond f value social our to reflect intended are results The society. on have activities business its impact (FES) social and tal applied a methodology for valuing the f and tested developed, has Novartis years, past the Over Doing business responsibly nancial performance, taking into account bene nancial, environmen f ts - - 45

Our responsibility 46

accidents, resulting in a total of 66 days of absence. days of 66 atotal in resulting accidents, from third staff loan and associates Novartis for longer or day of one pational accidents and diseases resulting in an absence at 0.13 occu stood rate Switzerland in accident the 2018, In system. management safety of the part as treated be will hazards these with dealing ous energy sources’. In the new guidelines and provisions, hazard ‘handling and at heights’ ‘working including activity, hazards/ different 10 around out sets program The future. the in accidents serious potentially of preventing aim the with investigated are incidents and accidents all program, Fatalities) and Injuries (Severe SIF our with line In Safety ment, and recovery. move nutrition, mindset, around choices right the through levels energy their manage everyone to help strategies core of four consists approach holistic The everywhere. and day every self best their to be at Novartis everyone to ignite aims that initiative global anew Life, for Energized we launched 2018 In paramount. are associates of our being well and health the and atmosphere work A decent Health -party companies.-party We recorded 15 occupational f elds of elds - - - tory. re is buildings of new impact the 24%. While by around fallen has zerland Swit in of Novartis consumption energy the 2013, Since energy is consumed. way the changing least not and heating of district use our increasing buildings, new, energy-efficient by constructing objectives these supporting we are Switzerland, In 2030. by reduction a50% and by 2020, emissions gas house green- global our in reduction a30% to achieve is goal Our Energy and greenhouse gas emissions Environment increased use of IT and growing automation in the labora the in automation growing and of IT use increased above-mentioned measures are almost canceled out by the the from resulting savings The consumption. electricity in reduction aslight seeing only weare things, other amongst 2 000TJ 1 000TJ 1 500TJ 500 TJ 13 fl 14 ected in the reduced level of heating used, used, of heating level reduced the in ected 15 16 17 18 Fossil Electricity Use of fuels heating consumption & other energy - - 47

Our responsibility 48

also fallen by 20%. fallen also f last the In trend. downward amarked is there too, Here volume. waste total of the 11–14% only for accounts waste Municipal f last the over by 25% reduced been has it Switzerland, In used. processes production the on heavily depends generated waste of hazardous volume The possible. as waste much as recycling or of waste generation the reducing at either aimed therefore environmental objectives of Novartis. Many measures are key of the one is of waste volume overall the Reducing Waste 60,000 t 40,000 t 30,000 t 20,000 t 50,000 t 10,000 t ve years, the speci the ve years, 14 15 16 17 f c volume of municipal waste has has waste of municipal c volume 18 of Municipal of Hazardous which which ve years. recycled recycled waste, waste, waste waste worldwide got involved, including 2,900 in Switzerland. in 2,900 including involved, got worldwide charitable project. In 2018, more than associates 23,900 alocal, on working aday to spend associates Novartis for opportunity an is Day Partnership Community annual The communities local in Engagement and juveniles. soup kitchens and contact centers for parents, children charitable organizations, neighborhood meeting points, example, Novartis makes substantial contributions to local advantaged people are sponsored in a variety of ways. For dis help that initiatives and institutions sphere, social the In Fostering social affairs of Novartis. sites company to the proximity geographic close in or interests business to our related either are that activities on is support of this focus main The sports. and culture of fostering the and affairs social relief, various initiatives and projects in humanitarian emergency in engages Novartis Donations, and Sponsoring its With Sponsoring donations and - 49

Our responsibility 50

Sponsoring culture In the area of culture, Novartis cultivates long-standing partnerships with well-known institutions, such as the Fondation Beyeler, Kunstmuseum Basel, and the Kunsthaus Baselland, as well as with the Basel Museumsnacht and the Theater Basel. Novartis is also a principal sponsor of the Baloise Session.

Sponsoring sports In the ﬁeld of sports, Novartis serves as the main sponsor of FC Basel and the basketball team Starwings Basket Regio Basel. In central Switzerland, Novartis is the Official Health Care Partner of the EV Zug hockey team. We also support the junior sections of various football clubs in the Basel region as well as various running sports events. ENGLISH EDITION 2019